Bad Blood: Secrets and Lies in a Silicon Valley Startup (2018)
Book Details
Bad Blood: Secrets and Lies in a Silicon Valley Startup (2018)
Jump to Section
⚠️ Trigger Warnings
- Suicide
- Workplace abuse
- Workplace intimidation
- Toxic workplace
- Bullying
- Stalking
- Legal harassment
- Medical malpractice
- Medical trauma
- Medical negligence
- Medical gaslighting
- Medical testing
- Blood
- Blood draws
- Finger pricks
- Needles
- Serious illness
- Cancer
- HIV
- Syphilis
- Sexual assault (mentioned)
- Alcoholism
- Gun violence
- Firearms
- Death of a family member
⏱️ 2-Minute Spoiler Summary
Bad Blood tells the true story of the spectacular rise and collapse of Theranos, a Silicon Valley startup founded by Elizabeth Holmes, who promised to revolutionize healthcare with a machine that could perform hundreds of blood tests using just a few drops of blood. Charismatic and relentlessly ambitious, Holmes convinces investors, politicians, and major companies like Walgreens and Safeway that her technology is the future of medicine, even though it rarely works. Inside Theranos, employees struggle with impossible technical problems while Holmes and her second-in-command, Sunny Balwani, foster a culture of secrecy, fear, and deception. Failed demonstrations are staged, investors are misled, and many patient samples are secretly tested on traditional laboratory machines instead of Theranos devices.
The company’s carefully crafted image begins to crumble when former employees become whistleblowers and share evidence with Wall Street Journal reporter John Carreyrou. Despite an aggressive campaign of legal threats and intimidation, Carreyrou publishes a series of investigations exposing the fraud. Regulators soon discover that Theranos’s testing practices put patients at risk, forcing the company to void nearly one million blood test results. Partnerships collapse, investors lose vast sums of money, and Theranos shuts down. The book ends with Holmes and Balwani facing fraud charges, revealing how charisma, secrecy, and unchecked ambition allowed one of the biggest corporate scandals in Silicon Valley history to flourish for more than a decade.
📖 Full Spoiler Summary
Elizabeth Holmes Wants to Change the World
Bad Blood begins with a young Elizabeth Holmes, a Stanford engineering student who has already decided that ordinary success isn’t enough. Since childhood, she’s dreamed of becoming a billionaire and changing the world. Inspired by Silicon Valley legends like Steve Jobs, she believes the fastest path is to drop out of college and build a revolutionary company.
At just nineteen, she leaves Stanford and founds Theranos. Her original idea is a wearable patch that can both diagnose illnesses and deliver medicine automatically. Stanford professor Channing Robertson is so impressed by her ambition that he joins the company and lends it immediate credibility. Elizabeth also hires Shaunak Roy, another young Stanford student, as her first employee.
Almost immediately, however, reality collides with ambition. The patch proves impossible to build. Rather than admitting failure, Elizabeth quietly changes the company’s mission. Instead of treating disease, Theranos will focus solely on diagnosing it using tiny blood samples collected from a finger prick.
The vision is breathtaking: hundreds of laboratory tests performed from just a few drops of blood using a portable machine. Investors love the idea, and Elizabeth proves to be an extraordinarily persuasive storyteller. She projects absolute confidence, dresses in black turtlenecks like Steve Jobs, lowers her voice into a distinctive monotone, and speaks about transforming healthcare as though success is inevitable.
The problem is that the technology doesn’t actually work.
Building a Company on Promises
Theranos spends years trying to create its first machine, eventually known as the Theranos 1.0. Engineers struggle with problems that seem impossible to overcome. Blood testing is already a complex scientific process requiring precise equipment, controlled environments, and relatively large samples. Theranos is trying to shrink an entire laboratory into a desktop-sized box.
Elizabeth refuses to accept delays or bad news. Employees quickly learn that telling her something cannot be done is a career-ending mistake.
One of the company’s biggest early opportunities comes when pharmaceutical giant Novartis invites Theranos to demonstrate its technology in Switzerland. The visit could lead to a valuable partnership.
Unfortunately, the devices fail.
Rather than admit defeat, Elizabeth and bioinformatics head Tim Kemp secretly arrange for pre-recorded data to be transmitted during the demonstration. As the machines appear to analyze blood samples, perfect results magically appear on screen. Novartis executives leave believing they’ve witnessed a breakthrough when, in reality, they’ve seen an elaborate illusion.
Inside the company, similar deception becomes increasingly common.
Chief Financial Officer Henry Mosley eventually realizes Theranos is misleading investors about the state of its technology. He confronts Elizabeth and argues that the company cannot continue making claims it knows are false.
Instead of listening, Elizabeth fires him immediately.
From that point on, anyone who challenges the company’s narrative is treated as an enemy.
A Culture of Fear
As Theranos grows, Elizabeth recruits experienced engineers to transform rough prototypes into real medical devices. One of them, Ed Ku, believes he can solve many of the company’s engineering problems.
He soon discovers that technical obstacles aren’t the biggest issue.
Elizabeth demands impossible deadlines and expects employees to work around the clock. When Ku refuses to require engineers to maintain an endless 24/7 schedule, he is dismissed. Much of his work is abandoned, forcing the company to begin again with a different design.
A new machine, eventually called the Edison, is built under engineer Tony Nugent. Instead of being a revolutionary invention, it relies heavily on existing laboratory technology squeezed into an awkward automated system. Even then, it frequently malfunctions.
Around the same time, Elizabeth’s boyfriend Sunny Balwani becomes increasingly involved behind the scenes. Although he has no medical or scientific background, he gradually assumes enormous authority before officially joining as president and chief operating officer.
Sunny transforms Theranos into an intensely secretive workplace.
Employees are divided into isolated departments that aren’t allowed to communicate with one another. Security cameras monitor offices, emails are scrutinized, and workers are constantly reminded that discussing projects—even with coworkers—is forbidden. Anyone suspected of disloyalty is fired immediately.
Fear replaces collaboration.
Instead of solving problems together, engineers become terrified of being blamed for failures they cannot fix.
Powerful Friends Believe the Dream
Even as the technology continues failing internally, Elizabeth becomes increasingly successful at attracting influential supporters.
Theranos assembles one of the most prestigious boards in Silicon Valley history. Former Secretary of State Henry Kissinger, former Secretary of State George Shultz, former Senator Sam Nunn, retired Marine General James Mattis, and other distinguished political figures all join the board.
Few have expertise in laboratory medicine.
Instead, they are captivated by Elizabeth herself. She presents Theranos not merely as a business but as a humanitarian mission that will make healthcare cheaper, faster, and more accessible.
Their reputations convince investors that someone else must have verified the science.
Elizabeth uses that credibility to pursue enormous retail partnerships.
Safeway CEO Steve Burd envisions blood-testing clinics inside hundreds of grocery stores. Walgreens executives Jay Rosan and Wade Miquelon become equally enthusiastic, believing Theranos will fundamentally change pharmacy healthcare.
Experts repeatedly warn them to slow down.
Laboratory consultant Kevin Hunter points out that Theranos refuses to produce scientific validation. Military physician Lt. Col. David Shoemaker refuses to endorse the technology for battlefield use because it has not passed proper regulatory review.
Their warnings are largely ignored.
Executives become so captivated by Elizabeth’s confidence that they commit hundreds of millions of dollars before the technology has proven it can reliably perform even basic blood tests.
The Technology Never Works
Behind closed doors, engineers continue chasing a solution that remains frustratingly out of reach.
Theranos begins developing an improved machine called the miniLab, also known internally as the 4S. Engineers Kent Frankovich and Greg Baney spend years trying to make it functional, but every new version develops fresh problems. Hardware breaks unexpectedly, chemical reactions fail, software crashes, and test results fluctuate wildly.
Patients are beginning to rely on Theranos for medical decisions, yet the machines still cannot consistently produce accurate answers.
Rather than admit failure, employees devise increasingly elaborate workarounds.
Daniel Young and engineer Sam Gong secretly modify commercial Siemens laboratory analyzers so they can process tiny finger-stick blood samples. Because those machines were never designed for such small quantities, the blood has to be diluted, reducing accuracy even further.
Partners like Walgreens believe Theranos is using revolutionary proprietary devices.
In reality, many patient samples are being tested on conventional laboratory equipment hidden from public view.
The deception extends beyond investors and business partners to doctors and patients, many of whom receive laboratory results that may be inaccurate.
A Tragedy Inside Theranos
Among the people most disturbed by the company’s direction is chief scientist Ian Gibbons.
Unlike many executives, Ian deeply understands laboratory science. He also recognizes that Theranos is making promises its technology cannot fulfill.
At the same time, Elizabeth becomes involved in a bitter patent dispute with inventor Richard Fuisz, a longtime family acquaintance.
Ian is caught in the middle.
Theranos lawyers pressure him for testimony while his own conscience tells him the company is misleading the courts. Already struggling with serious health issues, he becomes overwhelmed by the impossible position he’s been placed in.
Shortly before he is scheduled to testify, Ian attempts suicide and later dies.
His death devastates many employees and becomes one of the clearest examples of the emotional toll Theranos’s culture has taken on the people inside the company.
The Whistleblowers Speak
For years, Theranos manages to keep its problems hidden.
That begins to change when pathologist Adam Clapper, who writes an industry blog, contacts Wall Street Journal reporter John Carreyrou and suggests he investigate the company.
Carreyrou initially knows little about laboratory medicine, but as he starts interviewing former employees, a consistent picture emerges.
Former laboratory director Alan Beam describes widespread technical failures.
Young employee Erika Cheung explains how inaccurate testing has become routine.
Perhaps most importantly, Tyler Shultz—George Shultz’s grandson—decides he can no longer stay silent.
Tyler knows speaking out may destroy his relationship with his grandfather, who remains one of Elizabeth’s strongest supporters. Nevertheless, he begins cooperating with Carreyrou.
Theranos responds aggressively.
High-profile attorney David Boies and his law firm threaten whistleblowers with devastating lawsuits. Investigators follow former employees. Confidentiality agreements are weaponized. Tyler is even confronted inside his grandfather’s home by company lawyers demanding he reveal Carreyrou’s sources.
The intimidation campaign succeeds in frightening many people.
It does not stop the reporting.
Everything Falls Apart
In October 2015, The Wall Street Journal publishes John Carreyrou’s first investigation.
The article reveals that Theranos’s celebrated technology is largely a myth.
The company’s response is immediate. Elizabeth insists the story is false and portrays Theranos as the victim of unfair journalism.
But regulators begin looking more closely.
Inspectors from the Centers for Medicare & Medicaid Services, led by Gary Yamamoto, inspect Theranos’s laboratory in Newark, California. Their findings are devastating.
The lab is found to pose an “immediate jeopardy” to patient safety because of widespread deficiencies in testing procedures and quality controls.
Federal regulators impose sanctions.
Theranos is forced to void nearly one million blood-test results because they cannot be trusted.
Walgreens terminates its partnership after investing heavily in the company.
Investors who once viewed Elizabeth as the next Steve Jobs begin distancing themselves. Rupert Murdoch, who invested $125 million in Theranos, ultimately sells his shares back to the company for a symbolic one dollar.
The illusion that had taken more than a decade to construct unravels within months.
The End of the Unicorn
As investigations continue, more evidence emerges showing that Theranos systematically misled investors, business partners, regulators, physicians, and patients about the capabilities of its technology.
Employees who had once feared speaking publicly begin sharing their experiences. The carefully managed image of Elizabeth Holmes as a visionary entrepreneur gives way to a portrait of a leader who repeatedly chose deception over transparency whenever reality failed to match her promises.
In 2018, the Securities and Exchange Commission charges Elizabeth Holmes and Sunny Balwani with carrying out an elaborate years-long fraud against investors. Theranos dissolves soon afterward, ending one of the most spectacular corporate collapses in Silicon Valley history.
John Carreyrou closes the story by showing that Theranos wasn’t destroyed by one failed invention alone. Many startups experience technical setbacks. What ultimately doomed the company was its decision to conceal those failures while continuing to raise money, sign major partnerships, and provide medical test results to real patients.
Bad Blood ends not as the story of a revolutionary breakthrough that changed medicine, but as a cautionary tale about ambition without accountability. Elizabeth Holmes built one of the world’s most celebrated startups by convincing people to believe in a future that never existed, and for years, her charisma proved more powerful than scientific evidence—until the facts finally caught up with the story.
🔚 Ending Explained
The downfall of Theranos unfolds rapidly after John Carreyrou’s investigation in The Wall Street Journal exposes the company’s deception. What began as a Silicon Valley success story quickly unravels under mounting public scrutiny and government investigations.
Federal regulators inspect Theranos’s laboratory and conclude that its testing practices pose an “immediate jeopardy” to patient health. The company is forced to void or revise nearly one million blood test results after admitting that many of its proprietary tests were unreliable. Longtime partners including Walgreens and Safeway sever their relationships with the company, investors begin filing lawsuits, and Theranos’s carefully crafted reputation collapses almost overnight.
As the crisis deepens, Elizabeth Holmes attempts to keep the company alive by distancing herself from Sunny Balwani, who leaves Theranos amid the growing scandal. Despite repeated promises that the company can recover, Theranos continues burning through cash while its technology fails to deliver on years of extraordinary claims.
The legal consequences soon follow. In early 2018, the Securities and Exchange Commission (SEC) charges Holmes and Balwani with orchestrating what it describes as an “elaborate, years-long fraud.” Holmes settles the civil charges by paying a fine, surrendering voting control of the company, returning millions of shares, and accepting a ten-year ban from serving as an officer or director of a public company. By the book’s conclusion, Theranos is effectively running on borrowed time after consuming nearly $900 million in investor funding, while federal criminal charges against Holmes and Balwani appear increasingly inevitable.
Rather than ending with a dramatic courtroom verdict, Bad Blood concludes with the complete collapse of one of Silicon Valley’s most celebrated startups, leaving behind ruined careers, damaged reputations, and countless patients who unknowingly relied on inaccurate medical tests.
Thematic explanation of the ending
Appearance versus reality
The central irony of the ending is that nearly everything Theranos presented to the world was built on illusion.
Elizabeth Holmes cultivated the image of a visionary genius through carefully constructed symbolism—from her trademark black turtleneck to comparisons with Steve Jobs and a headquarters designed to project innovation and authority. As the fraud is exposed, each of these symbols loses its power. The company that once promised to revolutionize medicine is revealed to have relied largely on conventional laboratory equipment while hiding its failures behind secrecy and marketing.
The ending reinforces one of the book’s central messages: appearances can be manufactured, but scientific evidence cannot.
The importance of individual courage
Although Theranos seemed untouchable for years, its downfall ultimately begins because a handful of ordinary people choose to tell the truth.
Former employees Tyler Shultz and Erika Cheung risk their careers, finances, and personal relationships by exposing practices they believed endangered patients. They face intimidation, lawsuits, surveillance, and enormous pressure to remain silent, yet continue cooperating with regulators and journalists.
Their actions demonstrate that institutions often change not because powerful people intervene, but because individuals refuse to ignore wrongdoing.
Elizabeth Holmes’s choices
The ending presents Holmes not as someone undone by a single mistake but by years of increasingly consequential decisions.
Whenever faced with evidence that the technology did not work, she consistently chose secrecy, aggressive public relations, and continued fundraising instead of transparency. Even as regulators closed in, she remained publicly optimistic about Theranos’s future rather than acknowledging the company’s fundamental problems.
Carreyrou portrays this pattern as the defining characteristic of her leadership: protecting the company’s narrative became more important than confronting reality.
Tone
The book ends with a tone of vindication mixed with tragedy.
There is satisfaction in seeing the fraud exposed and patients protected, but the victory comes only after years of unnecessary harm. Employees lost careers, investors lost hundreds of millions of dollars, and patients received inaccurate medical information that could have affected life-altering health decisions.
The collapse therefore feels less triumphant than cautionary.
Major themes reinforced by the ending
Ambition without accountability
Bad Blood never argues that ambition itself is the problem. Instead, it shows how extraordinary ambition becomes dangerous when it is no longer constrained by evidence, ethics, or accountability.
Holmes repeatedly convinced herself—and others—that success justified increasingly deceptive behavior.
The limits of “fake it until you make it”
One of the book’s strongest arguments is that Silicon Valley’s culture of exaggeration may be survivable in software, where products can improve after launch, but it becomes dangerous in healthcare.
Medical testing demands accuracy from the outset because real patients base life-changing decisions on those results. Theranos blurred the line between technological optimism and medical responsibility, with serious consequences.
Charisma is not expertise
Another enduring lesson is how easily accomplished people can be persuaded outside their own fields.
Theranos assembled one of the most prestigious corporate boards in America, filled with former diplomats, military leaders, and politicians. Yet very few possessed meaningful expertise in laboratory medicine. Their confidence in Holmes lent credibility to claims they were not equipped to evaluate critically.
The ending suggests that impressive credentials and influential supporters are poor substitutes for independent scientific validation.
What the ending means
Ultimately, Bad Blood is not simply the story of Elizabeth Holmes or Theranos. It is a warning about what can happen when charisma, secrecy, and unchecked ambition are allowed to eclipse evidence and accountability.
The company’s collapse serves as a reminder that innovation cannot replace scientific rigor, particularly in medicine, where people’s health depends on the truth. By ending before the later criminal trials, Carreyrou leaves readers with the sense that the exposure of the fraud—not the eventual punishment—is the true climax. The real victory belongs to the journalists, scientists, regulators, and whistleblowers who insisted that extraordinary claims required extraordinary proof.
👤 Characters & Fates
🔶 Main Characters
🔷 Supporting Characters
🕳️ Potential Plot Holes
Because Bad Blood is an investigative work of non-fiction, any apparent "plot holes" are not flaws in John Carreyrou's storytelling. Instead, they are contradictions, inconsistencies, and gaps between the narrative Theranos presented to investors, regulators, employees, and the public and what was actually happening behind the scenes. These discrepancies ultimately became key pieces of evidence exposing the company's fraud.
Theranos frequently claimed it could not answer technical questions because its blood-testing technology was protected as a highly sensitive trade secret.
- The claim: Elizabeth Holmes and other executives insisted that revealing details about their testing process would expose proprietary technology to competitors such as Quest Diagnostics and Labcorp.
- The inconsistency: When The Wall Street Journal asked whether Theranos was using the commercially available Siemens ADVIA analyzer, the company refused to answer, again citing trade secrets. However, the operation of a third-party analyzer manufactured by Siemens was not proprietary to Theranos, making the explanation difficult to reconcile with reality.
Theranos repeatedly gave dramatically different accounts of what its technology could actually do.
- The public claim: Holmes and Sunny Balwani told investors that Theranos could perform approximately 98% of the 300 most common blood tests using just a finger-stick blood sample.
- The reality: Internal records and later regulatory findings showed that the Edison device could perform only about 12 specific tests. Most other tests were either unavailable or processed on conventional laboratory analyzers using diluted blood samples.
The company's financial projections varied dramatically depending on the audience.
- Presented to investors: In 2014, Sunny Balwani projected approximately $261 million in annual revenue, portraying Theranos as a rapidly growing business.
- Presented internally: Around the same time, corporate controller Danise Yam estimated revenue at only about $50 million when valuing employee stock options. The enormous gap between these figures became one of the examples cited in later fraud investigations.
Theranos also maintained a misleading narrative about its leadership.
- The public narrative: Elizabeth Holmes cultivated the image of a single-minded founder devoted entirely to the company. She even told senior employees that her relationship with Sunny Balwani had ended and was now strictly professional.
- The reality: Holmes and Balwani were still romantically involved and living together throughout much of Theranos's rise, a fact that remained hidden from many employees, board members, and the public.
Theranos's treatment of one of its published studies shifted depending on what best supported its position.
- When defending the company: Holmes cited a peer-reviewed paper published in Hematology Reports as evidence that Theranos's technology had been scientifically validated.
- When challenged: After The Wall Street Journal questioned the strength of the same study, executive Daniel Young dismissed it as outdated research based on technology the company supposedly no longer used.
Theranos pursued an aggressive legal campaign that was difficult to reconcile with the available evidence.
- The allegation: The company accused Richard and John Fuisz of stealing confidential Theranos patent information through the law firm McDermott Will & Emery.
- The evidence: A review of the firm's records found no indication that John Fuisz or his secretary had ever accessed Theranos's confidential files. Despite the lack of supporting evidence, Theranos continued pursuing the allegation for years.
One of the company's most public demonstrations also proved to be misleading.
- The presentation: During Vice President Joe Biden's 2015 visit, Theranos showcased an impressive room filled with sleek miniLab devices, describing it as the laboratory of the future.
- The reality: The display was largely staged. The functioning clinical laboratory was located elsewhere in the building, and many employees were instructed to stay home during the visit to reduce the risk of anyone inadvertently revealing how patient testing was actually being performed.
These contradictions form one of the central themes of Bad Blood. Rather than revealing weaknesses in the book itself, they illustrate the widening gap between Theranos's carefully crafted public image and the company's actual operations, a discrepancy that investigative reporting, whistleblowers, and regulators gradually uncovered.
📚 Book Club Q&A's
⭐ Final Rating & Thoughts
Bad Blood is one of those rare nonfiction books that reads with the suspense of a thriller while remaining firmly grounded in meticulous investigative reporting. I went into it hoping to understand how Elizabeth Holmes managed to convince so many intelligent, influential people that Theranos was the future of medicine, and while I didn't come away with every answer, I did leave with a much deeper appreciation for the complexity of the story. John Carreyrou carefully documents how ambition, secrecy, and unchecked confidence created one of the biggest corporate frauds in modern history. Although the middle section became somewhat repetitive as similar patterns emerged across different employees, the depth of reporting more than justified it. What has stayed with me most isn't simply the fraud itself, but the lingering questions about Holmes's mindset and whether she believed her own promises. It's a fascinating, thought-provoking read that is both infuriating and impossible to put down.
✨ Adaptation description
The planned film adaptation of Bad Blood, based on John Carreyrou’s bestselling investigation into Theranos founder Elizabeth Holmes, is effectively shelved after Jennifer Lawrence exited the project.
Originally announced by Legendary Pictures before moving to Apple Original Films, the movie was set to be written and directed by Adam McKay. Jennifer Lawrence was attached to star as Elizabeth Holmes and also serve as a producer. The film was based on Bad Blood: Secrets and Lies in a Silicon Valley Startup, Carreyrou’s acclaimed nonfiction account of the rise and collapse of Theranos.
However, the project lost momentum after Lawrence decided to step away. She later explained that watching Amanda Seyfried’s acclaimed performance as Holmes in Hulu’s 2022 limited series The Dropout convinced her the story had already been told exceptionally well. Reflecting on her decision, Lawrence said, “I thought she was terrific. I was like, ‘Yeah, we don’t need to redo that.’ She did it.”
With Lawrence’s departure and no replacement announced, the Bad Blood feature film is widely considered to be on indefinite hold.
✨ Books Like Bad Blood: Secrets and Lies in a Silicon Valley Startup (2018)
See an error on this page?